Benefits of osimertinib treat a lung adenocarcinoma patient with germline EGFR T790M, somatic EGFR 19-Del, TP53 and PIK3CA mutations

Benefits of osimertinib treat a lung adenocarcinoma patient with germline EGFR T790M, somatic EGFR 19-Del, TP53 and PIK3CA mutations

Abstract Background Somatic mutations in the EGFR gene occur in about 50% of non-small cell lung cancers, with the T790M mutation significantly contributing to secondary resistance against EGFR-TKI drugs. However, EGFR T790M germline mutations rarely occur. Case presentation In this study, we report...

Full description

Bibliographic Details
Main Authors: Yingxue Li, Guangqi Li, Zheng Zheng, Wenjuan Wen, Haihui Zhao, Xia Liu, Jiaping Xie, Lin Han
Format: Article
Language:English
Published: BMC 2024-08-01
Series:Hereditary Cancer in Clinical Practice
Subjects:
Germline T790M mutation
Somatic EGFR 19-Del mutations
PIK3CA mutation
Lung adenocarcinoma
Osimertinib
Online Access:https://doi.org/10.1186/s13053-024-00286-4

Internet

https://doi.org/10.1186/s13053-024-00286-4

Similar Items